Bharat Biotech
Indian biotechnology company and vaccine manufacturer
Bharat Biotech ▸ Facts ▸ Comments ▸ News ▸ Videos
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in Hyderabad, engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.
| 0 shares | ShareTweetSavePostSend |
You Might Like
Covaxin supply to hit 5.5 cr doses from October: Bharat Biotech chairmanCovaxin output is all set to be ramped up to 5.5 crore doses in October from to 3.5 crore doses in September, Bharat Biotech’s chairman & managing director Dr Krishna Ella said on Tuesday. Pointing..IndiaTimes - Published | |
Covaxin kids trial over, Bharat Biotech to submit data to DCGI next weekIndiaTimes - Published | |
Covaxin may soon get WHO approval as expert group scheduled to meet next monthSAGE members and Bharat Biotech officials will hold a meeting where safety and efficacy of Covaxin will be discussed on the basis trial data in India.DNA - Published | |
Bharat Biotech awaits feedback from WHO for Covid-19 vaccine Covaxin's emergency use listingIndiaTimes - Published | |
AIIMS Delhi to conduct phase 2/3 clinical trials for Bharat Biotech's nasal COVID vaccineDelhi AIIMS is one of the three hospitals where the phase 2 and 3 trials of Bharat Biotech's intranasal vaccine will be conducted.DNA - Published Also reported by •IndiaTimes | |
First batch of Covaxin rolls out of Gujarat plant of Bharat BiotechIndiaTimes - Published | |
First commercial batch of Covaxin rolls out from Bharat Biotech's Ankleshwar plantIn a move that will augment the supply of indigenously developed Covid-19 vaccine Covaxin, Bharat Biotech on Sunday announced the rollout of the first commercial batch of Covaxin from its Chiron..IndiaTimes - Published | |
1 Covaxin dose to survivor equals 2 doses to uninfectedA single-dose of Bharat Biotech’s Covaxin in people who had been infected with Covid-19 previously generates antibody response similar to that provided by two doses of the vaccine in those without..IndiaTimes - Published | |
Covid vaccination for kids may start only by March ’22Zydus Cadila's Covid-19 vaccine, ZyCoV-D, is expected to get an emergency use authorisation for the 12-18 cohort by end of August, whereas Bharat Biotech’s Covaxin – the world’s only vaccine..IndiaTimes - Published | |
Bharat Biotech's intransal Covid vaccine gets nod for phase II/III trialsIndiaTimes - Published | |
75 million Covaxin doses supplied, more by September, says Bharat Biotech's Suchitra EllaIndiaTimes - Published | |
Union health minister Mansukh Mandaviya meets WHO Chief Scientist Dr Soumya Swaminathan, discusses WHO's approval of CovaxinUnion health minister Mansukh Mandaviya on Thursday met World Health Organization (WHO) Chief Scientist Dr Soumya Swaminathan and held a discussion over the world body's approval of Bharat Biotech's..IndiaTimes - Published | |
Govt approves Bharat Biotech's Ankleshwar plant for manufacturing CovaxinUnion health minister Mansukh Mandaviya on Tuesday said the government has approved Bharat Biotech’s vaccine manufacturing facility at Ankleshwar in Gujarat for manufacturing India’s first..IndiaTimes - Published | 136 crore Covishield, Covaxin doses to lead India's vaccination drive during August-DecemberMore than 136 crore Covid-19 vaccine doses are expected to be available till the end of this year, informed the Centre. For the next four months, India's vaccine programme will be accelerated by the..IndiaTimes - Published |
Bharat Biotech issues clarification on quality concerns with CovaxinThe statement came after reports that test batches of Covaxin were not satisfactory and got rejected leading to delayed production.DNA - Published | Covaxin output set to rise; govt hopes to meet 135 crore-dose goalIndian Immunologicals Limited is likely to start supply of an additional 2 million doses of Covaxin from August-September, whereas Bharat Biotech’s Ankleshwar facility is likely to add 6 million..IndiaTimes - Published |
Brazil's Anvisa provisionally suspends authorisation for exceptional import of 4 million Covaxin dosesAfter closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotech’s Covaxin, Brazil’s health regulator Anvisa (Agencia Nacional de Vigilancia Sanitaria)..IndiaTimes - Published | Brazil suspends Bharat Biotech imports permitIndiaTimes - Published |
After suspending Covaxin clinical trials, Brazil closes EUA requestAfter suspending the clinical trials of Covaxin following the termination of Bharat Biotech's MoU with its Brazilian partner Precisa Medicamentos, Brazil’s health regulator Anvisa (Agencia Nacional..IndiaTimes - Published | Bharat Biotech terminates pact with Brazil partners Precisa Medicamentos, Envixia PharmaIndiaTimes - Published |
Bharat Biotech commits to supply 500 million doses of Covaxin to Centre for immunisation programmeBharat Biotech on Friday said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation programme.IndiaTimes - Published | AIIMS to begin second dose trial of Bharat Biotech's Covaxin on children between 2-6 yearsNot just Bharat Biotech's Covaxin but Zydus Cadila's vaccine for children is also currently under trial in IndiaDNA - Published |
Bharat Biotech dossier under review for Covaxin emergency use listing: WHOIndiaTimes - Published | Submitted all required documents to WHO for EUL: Bharat BiotechIndiaTimes - Published |
WHO Chief Scientist Dr Swaminathan says phase-3 trials of Covaxin look good, Bharat Biotech awaits approvalA few days ago, Bharat Biotech had released the phase 3 clinical trial results of Covaxin after evaluating 130 symptomatic COVID-19 cases.DNA - Published | Covaxin's overall efficacy 77.8%, 65.2% effective against Delta variant: Bharat BiotechIndiaTimes - Published |
Bharat Biotech says vaccine 93.4% effective against severe Covid-19Phase-III trials of Covaxin, made by Hyderabad's Bharat Biotech showed it was 93.4% effective against severe symptomatic Covid-19, the firm said on Saturday. The data demonstrated 65.2% protection..IndiaTimes - Published | Inching towards WHO's emergency use approval for Covaxin: Bharat BiotechIndiaTimes - Published |
Bharat Biotech denies receiving advance payments, supplying vaccines to BrazilIndiaTimes - Published | Bharat Biotech slams allegations of wrongdoing in Covaxin procurement deal in BrazilIndiaTimes - Published |
Brazil suspends Bharat Biotech s Covaxin order over graft allegationsIndiaTimes - Published | Bharat Biotech chairman given central security coverIndiaTimes - Published |
'Bharat Biotech's Covaxin shows 77.8% efficacy in phase 3 trials'Bharat Biotech's Covaxin has demonstrated 77.8% efficacy in phase 3 trials, reported ANI quoting sources. The Hyderabad-based firm had earlier submitted the trial data to the Subject Expert Committee..IndiaTimes - Published | Bharat Biotech has submitted Covaxin's Phase III trial data to DCGI: Govt sourcesIndiaTimes - Published |
Covid-19: WHO accepts expression of interest for Covaxin emergency use listingCovaxin has inched a step closer to a World Health Organization (WHO) emergency use listing (EUL) with the global body accepting Bharat Biotech’s expression of interest (EoI) for the inactivated..IndiaTimes - Published | Bharat Biotech, WHO pre-submission meeting on June 23: WHOHyderabad-based Bharat Biotech's pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation (WHO)'s Emergency Use Listing (EUL) of its indigenous COVID-19..IndiaTimes - Published |
Covaxin does not contain newborn calf serum, say Bharat Biotech and govtIndiaTimes - Published | Fact Check: No newborn calf serum in Covaxin, Health Ministry and Bharat Biotech confirmThe final vaccine does not contain newborn calf serum at all as the calf serum is not an ingredient of the final vaccine product, Health Ministry saidDNA - Published |
Covaxin does not contain newborn calf serum: Centre busts mythsThe indigenously developed Covaxin does not contain newborn calf serum, clarified Centre on Wednesday. The statement came in response to some social media posts which the government said have "twisted..IndiaTimes - Published | SII, Bharat Biotech seek hike in government price for Covid vaccinesSerum Institute of India (SII) and Bharat Biotech (BB) are seeking higher prices for Covid-19 vaccines from the Centre amid concerns that the cost of Covishield and Covaxin shots in private hospitals..IndiaTimes - Published |
Bharat Biotech says Rs 150 per Covaxin dose to government not sustainableThe vaccine maker has said that it had to invest over Rs 500 crore at risk from its resources for product development, clinical trials, manufacturing.DNA - Published | Covaxin average price realisation less than Rs 250 per dose: Bharat BiotechIndiaTimes - Published |
CISF takes over security of Bharat Biotech plantIndiaTimes - Published | CISF takes over security of Covaxin manufacturer Bharat Biotech's Hyderabad campusIndiaTimes - Published |
Covaxin maker Bharat Biotech gets CISF cover of 64 personnelIndiaTimes - Published | Can person with any allergy take COVID-19 shots? Know what experts sayBharat Biotech, the manufacturer of the COVID-19 vaccine said that those who have known allergies to any component of Covaxin should not take the jab.DNA - Published |
Committed to data transparency on Covaxin, published 9 papers in 12 months: Bharat BiotechIndiaTimes - Published | Ocugen to seek emergency nod for Covaxin from Health CanadaBharat Biotech’s US partner Ocugen said it will be seeking an emergency use nod for India’s first indigenously developed Covid-19 vaccine Covaxin from the Canadian health authorities. The company..IndiaTimes - Published |
Ocugen to seek full approval for Covaxin in US via BLA instead of EUABharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be pursuing the biologics license application..IndiaTimes - Published | Ocugen to take BLA route for Covaxin in US based on FDA recommendation; seek emergency use nod for CanadaBharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be pursuing the biologics license application..IndiaTimes - Published |
